159 related articles for article (PubMed ID: 36253240)
21. Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms.
Valenzuela CD; Mangieri CW; Garland-Kledzik M; Gawdi R; Russell G; Perry KC; Votanopoulos KI; Levine EA; Shen P
Ann Surg Oncol; 2022 Jun; 29(6):3422-3431. PubMed ID: 35254575
[TBL] [Abstract][Full Text] [Related]
22. Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Garach NR; Kusamura S; Guaglio M; Bartolini V; Deraco M; Baratti D
Eur J Surg Oncol; 2021 May; 47(5):1132-1139. PubMed ID: 33280949
[TBL] [Abstract][Full Text] [Related]
23. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
24. An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Mercier F; Passot G; Bonnot PE; Cashin P; Ceelen W; Decullier E; Villeneuve L; Walter T; Levine EA; Glehen O; ;
World J Surg; 2022 Jun; 46(6):1336-1343. PubMed ID: 35286418
[TBL] [Abstract][Full Text] [Related]
25. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.
Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA
Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583
[TBL] [Abstract][Full Text] [Related]
26. The impact of HIPEC
Leiting JL; Day CN; Harmsen WS; Cloyd JM; Abdel-Misih S; Fournier K; Lee AJ; Dineen S; Dessureault S; Veerapongh J; Baumgartner JM; Clarke C; Mogal H; Russell MC; Zaidi MY; Patel SH; Morris MC; Hendrix RJ; Lambert LA; Abbott DE; Pokrzywa C; Raoof M; Eng O; Johnston FM; Greer J; Grotz TE
Int J Hyperthermia; 2020; 37(1):1182-1188. PubMed ID: 33040617
[TBL] [Abstract][Full Text] [Related]
27. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
28. The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative.
Fackche N; Schmocker RK; Kubi B; Cloyd JM; Ahmed A; Grotz T; Leiting J; Fournier K; Lee AJ; Powers B; Dineen S; Veerapong J; Baumgartner JM; Clarke C; Gamblin TC; Patel SH; Dhar V; Hendrix RJ; Lambert L; Abbott DE; Pokrzywa C; Lafaro K; Lee B; Zaidi MY; Maithel SK; Johnston FM; Greer JB
J Gastrointest Surg; 2021 Nov; 25(11):2908-2919. PubMed ID: 33634422
[TBL] [Abstract][Full Text] [Related]
29. Extensive surgical history prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with poor survival outcomes in patients with peritoneal mucinous carcinomatosis of appendiceal origin.
Milovanov V; Sardi A; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 Jul; 41(7):881-5. PubMed ID: 25899982
[TBL] [Abstract][Full Text] [Related]
30. Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative.
Beal EW; Srinivas S; Shen C; Kim A; Johnston FM; Greer J; Abbott DE; Pokrzywa C; Raoof M; Grotz TE; Leiting JL; Fournier K; Dineen S; Powers B; Veerapong J; Kothari A; Maduekew U; Maithel S; Wilson GC; Patel SH; Lambert L; Abdel-Misih S; Cloyd JM
Ann Surg Oncol; 2023 Mar; 30(3):1840-1849. PubMed ID: 36310315
[TBL] [Abstract][Full Text] [Related]
31. Outcomes Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy with and without Diaphragmatic Resection in Patients with Peritoneal Metastases.
Nikiforchin A; Gushchin V; Sittig M; Baron E; Lopez-Ramirez F; Nieroda C; Sardi A
Ann Surg Oncol; 2022 Feb; 29(2):873-882. PubMed ID: 34546479
[TBL] [Abstract][Full Text] [Related]
32. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
Ihemelandu C; Mavros MN; Sugarbaker P
Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of neoadjuvant chemotherapy before CRS-HIPEC for patients with appendiceal cancer.
Chen JC; Beal EW; Hays J; Pawlik TM; Abdel-Misih S; Cloyd JM
J Surg Oncol; 2020 Sep; 122(3):388-398. PubMed ID: 32383206
[TBL] [Abstract][Full Text] [Related]
34. Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy.
Sutton PA; O'Dwyer ST; Barriuso J; Aziz O; Selvasekar CR; Renehan AG; Wilson MS
Surg Oncol; 2021 Sep; 38():101572. PubMed ID: 33915487
[TBL] [Abstract][Full Text] [Related]
35. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
Chang SC; Fingerhut A; Chen WT
Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
[TBL] [Abstract][Full Text] [Related]
36. Prolonged Survival in Peritoneal Metastatic Appendiceal Carcinoma Patients Treated With Combined Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Acs M; Gerken M; Zustin J; Blaj S; Isgandarova S; Piso P
J Surg Res; 2023 Mar; 283():839-852. PubMed ID: 36915011
[TBL] [Abstract][Full Text] [Related]
37. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Munoz-Zuluaga C; Sardi A; King MC; Nieroda C; Sittig M; MacDonald R; Gushchin V
Ann Surg Oncol; 2019 Feb; 26(2):473-481. PubMed ID: 30523470
[TBL] [Abstract][Full Text] [Related]
38. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
[No Abstract] [Full Text] [Related]
39. Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risk Primary Appendiceal Neoplasms After Complete Resection.
Enomoto LM; Choudry MH; Bartlett DL; Totin L; Mann GN; Skitzki JJ; Perry KC; Votanopoulos KI; Levine EA; Shen P
Ann Surg Oncol; 2020 Jan; 27(1):107-114. PubMed ID: 31368017
[TBL] [Abstract][Full Text] [Related]
40. Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC.
Ward EP; Okamuro L; Khan S; Hosseini M; Valasek MA; Ronquillo N; Kelly KJ; Veerapong J; Lowy AM; Baumgartner J
Hum Pathol; 2021 Jul; 113():104-110. PubMed ID: 33905776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
